Login / Signup

Side-by-side comparative study of the immunogenicity of the intramuscular and intradermal rabies post-exposure prophylaxis regimens in a cohort of suspected RABV exposed individuals.

Heidi AuerswaldAlvino MaestriSothy TouchSaraden InNisa YaBorita HengValérie Bosch-CastellsChristele AugardCéline PetitPhilippe DussartYiksing PengTineke CantaertSowath Ly
Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
All WHO pre-qualified rabies vaccines for humans are inactivated tissue culture rabies virus formulations produced for intramuscular (IM) administration. Due to costs and vaccine shortage, dose-saving intradermal (ID) administration of rabies post-exposure prophylaxis (PEP) is encouraged by WHO. This study compared the immunogenicity of the ID 2-site, 3-visit IPC PEP regimen to the IM 1-site, 4-visit 4-dose Essen regimen using Verorab vaccine (Sanofi). The development of neutralizing antibodies (nAbs) and T cell response was assessed in 210 patients with a category II or III animal exposure in a rabies-endemic country. At day 28, all participants developed nAbs (≥0.5 IU/mL), irrespective of PEP scheme, age, or administration of rabies immunoglobulin. T cell response and nAb titers were similar for both PEP schemes. This study demonstrated that the 1-week ID IPC regimen is as effective as the 2-week IM 4-dose Essen regimen in inducing an anti-rabies immune response under real-life PEP.
Keyphrases
  • immune response
  • pulmonary embolism
  • advanced non small cell lung cancer
  • dendritic cells
  • inflammatory response
  • dengue virus
  • visible light